Innovent Biologics (09969) climbed more than 6% during early Hong Kong trading, with gains moderating to 5.24% at press time to HK$17.26. Trading volume reached HK$194 million. The biopharmaceutical firm announced that its self-developed novel BCL2 inhibitor mesutoclax (ICP-248), combined with azacitidine for treating myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), has received U.S. Food and Drug Administration (FDA) clearance for clinical studies. Public documentation indicates mesutoclax is a novel oral highly selective BCL2 inhibitor. BCL2 serves as a critical regulatory protein in cellular apoptosis pathways, with its abnormal expression linked to development of various hematological malignancies. By selectively inhibiting BCL2, mesutoclax reactivates programmed cell death mechanisms in tumor cells to exert anti-tumor effects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。